Wednesday, March 01, 2017 10:43:23 PM
By Chris Sandburg / in Biotech & Pharma, Momentum & Growth, Momentum Stocks, Stocks / on Wednesday, 01 Mar 2017 11:07 AM
https://www.insiderfinancial.com/heres-our-take-on-premier-biomedical-inc-otcmktsbieis-strategy/119870/
IN THIS ARTICLE:
...The company’s extracorporeal platform is targeting a host of different indication types, with the major blockbusters all included – Alzheimer’s, oncology, CNS, autoimmune etc. These are great from a long term potential perspective...
This should bridge the gap between pre clinical and clinical development in the blockbusters described above... The pain relief patches consist of a proprietary CBD hemp oil formulation with 20% more CBD, and a patch area 30% larger, than competition. They are designed to provide up to 96 hours of continuous pain relief. The roll-on applicator contains 110 mg of Premier’s proprietary CBD formulation, 10% more CBD than the closest competitor. These are pretty decent specs, and there’s data in place that supports efficacy of both products. The key point here, however, is that these products don’t need FDA approval before commercialization. That’s the beauty of CBD rooted pain management, and that’s the core justification (in our eyes) for Premier moving into the space.
... These few distribution agreements aren’t going transform Premier’s financials overnight. They are, however, the first concrete reports that we’ve got that outlets are willing to hold Premier’s products on-shelf, and they represent (according to the company) the start of a much bigger distribution rollout.
As news of further outlets stocking the roll on and the patch hit press, we should see Premier pick up increased speculative interest, and with this added volume, we should see some strength.
As the products sell, we should also see some top line increase, and this will eat away at the dilutive risk (which is pretty large right now)...
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM